Dicembrini I, et al. - Researchers sought to ascertain the effect of Dipeptidyl Peptidase-4 inhibitors (DPP4i) on the incidence of pancreatitis and pancreatic cancer via performing a meta-analysis collecting all available evidence from randomized controlled trials. Searching Medline, Embase and Cochrane Database extensively for sitagliptin or vildagliptin or omarigliptin or saxagliptin or alogliptin or trelagliptin or anagliptin or linagliptin or gemigliptin or evogliptin or teneligliptin up to September 30, 2019, they identified 165 eligible trials. No correlation of DPP-4 inhibitors with an increased risk of pancreatitis or pancreatic cancer was observed; there were no significant discrepancies across individual molecules of the class. Available data thus do not support the hypothesis of a relationship of DPP4i treatment with pancreatitis.